Once-daily intraperitoneal cefazolin and oral ciprofloxacin as empiric therapy for the treatment of peritonitis

被引:0
作者
Troidle, L [1 ]
Gorban-Brennan, N [1 ]
Kliger, A [1 ]
Finkelstein, F [1 ]
机构
[1] Yale Univ, Sch Med, Renal Res Inst, New Haven CPD, New Haven, CT 06511 USA
来源
ADVANCES IN PERITONEAL DIALYSIS/1999, VOL 15 | 1999年 / 15卷
关键词
peritonitis; cefazolin; ciprofloxacin; outcome; treatment;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The Ad Hoc Advisory Committee on Peritonitis Management has recommended intraperitoneal (IP) cefazolin and an aminoglycoside as empiric therapy for the treatment of peritonitis. Because most of our patients are on continuous cycler therapy, we developed a strategy of once-daily IP cefazolin and or al ciprofloxacin as empiric therapy All patients in our unit that developed peritonitis were given a once-daily 2 g load of IP cefazolin, plus 500 mg ciprofloxacin orally, twice daily. Ciprofloxacin was given two hours after any, phosphate binder or iron supplement. The IP cefazolin was allowed to dwell for at least 5h hours. The dialysate was then drained and chronic peritoneal dialysis (CPD) resumed. Organisms sensitive to cefazolin were treated for 14 days with once-daily cefazolin alone, resistant organisms, were treated with alternative antibiotics. A total of 40 patients were treated with this empiric regimen, of these, 35 (88%) successfully continued CPD therapy, 1 (2%) transferred to hemodialysis, and 4 (10%) expired two weeks after the onset of peritonitis. A total of 22 patients (55%) were treated successfully with once-daily IP cefazolin. Although once-daily IP cefazolin and oral ciprofloxacin permitted continuation of CPD therapy in most patients in this study the therapy was not optimal. While vancomycin may have provided better coverage, recent reports of vancomycin-resistant enterococci and Staphylococcus aureus present a major concern.
引用
收藏
页码:213 / 216
页数:4
相关论文
共 10 条
  • [1] [Anonymous], 1995, INFECT CONT HOSP EP, V16, P105
  • [2] Outcomes of single organism peritonitis in peritoneal dialysis: Gram negatives versus gram positives in the Network 9 Peritonitis Study
    Bunke, CM
    Brier, ME
    Golper, TA
    [J]. KIDNEY INTERNATIONAL, 1997, 52 (02) : 524 - 529
  • [3] ORAL CIPROFLOXACIN IN THE TREATMENT OF PERITONITIS IN PATIENTS ON CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS
    FLEMING, LW
    PHILLIPS, G
    STEWART, WK
    SCOTT, AC
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1990, 25 (03) : 441 - 448
  • [4] KAZMI H, 1988, J AM SOC NEPHROL, V16, P128
  • [5] KEANE WF, 1993, PERITON DIALYSIS INT, V13, P14
  • [6] Keane WF, 1996, PERITON DIALYSIS INT, V16, P557
  • [7] Emergence of vancomycin resistance in Staphylococcus aureus
    Smith, TL
    Pearson, ML
    Wilcox, KR
    Cruz, C
    Lancaster, MV
    Robinson-Dunn, B
    Tenover, FC
    Zervos, MJ
    Band, JD
    White, E
    Jarvis, WR
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (07) : 493 - 501
  • [8] Differing outcomes of gram-positive and gram-negative peritonitis
    Troidle, L
    Gorban-Brennan, N
    Kliger, A
    Finkelstein, F
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 32 (04) : 623 - 628
  • [9] Nine episodes of CPD-associated peritonitis with vancomycin resistant enterococci
    Troidle, L
    Kliger, AS
    GorbanBrennan, N
    Fikrig, M
    Golden, M
    Finkelstein, FO
    [J]. KIDNEY INTERNATIONAL, 1996, 50 (04) : 1368 - 1372
  • [10] Troidle LK, 1998, ADV PERIT D, V14, P137